Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
https://www.zacks.com/stock/news/2290616/ionis-ions-expands-licensing-deal-with-otsuka-for-hae-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290616
Jun 19, 2024 - Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
0
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
https://seekingalpha.com/article/4697680-biogen-inc-biib-q1-2024-earnings-call-transcript?source=feed_sector_transcripts
Jun 05, 2024 - Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ETCompany ParticipantsChuck Triano - Head of Investor...
0
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
https://www.zacks.com/stock/news/2283576/denali-s-dnli-candidate-selected-for-fda-s-start-pilot-program?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2283576
Jun 04, 2024 - Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
0
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
https://www.zacks.com/stock/news/2282063/biogen-biib-gets-eu-approval-for-rare-disease-drug-qalsody?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282063
May 31, 2024 - Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2278558/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2278558
May 24, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
https://www.zacks.com/stock/news/2278671/the-zacks-analyst-blog-highlights-biogen-ionis-pharmaceuticals-gsk-ptc-therapeutics-and-larimar-therapeutics?cid=CS-ZC-FT-press_releases-2278671
May 24, 2024 - Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
0
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
https://www.zacks.com/stock/news/2278232/biotech-stock-roundup-biib-s-acquisition-ptct-lrmr-gain-on-updates-more-news?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2278232
May 23, 2024 - Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
0
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
https://www.zacks.com/stock/news/2277986/biogen-biib-to-buy-hi-bio-to-expand-rare-disease-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277986
May 23, 2024 - Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
0
Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2276642/why-biogen-inc-biib-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2276642
May 21, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
https://www.zacks.com/stock/news/2274368/biogen-biib-partner-begins-filing-for-leqembi-sc-autoinjector?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274368
May 15, 2024 - Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
0